# US 2021/0267936 A1 · Combination therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267936 A1
- Document ID: US20210267936A1
- Status: Published application
- Kind: A1
- Application number: 17/202,755
- Filed: 2021-03-16
- Published: 2021-09-02
- Earliest claimed: 2015-02-02
- Assignees: MEI Pharma, Inc.; The Spanish National Cancer Research Centre
- Applicants: MEI Pharma, Inc.; The Spanish National Cancer Research Centre
- Inventors: Daniel P. GOLD; Miguel QUINTELA-FANDINO
- Web page: https://patentgrep.com/patent/US20210267936A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/30: from tumour cells
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.

## Claims

### Claim 1

A method of treating a cancer that is breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, ovarian cancers, neuroblastoma, glioblastoma, kidney cancer, bladder cancer, gastrointestinal stromal tumors, liver cancer, head and neck cancer, lung cancer, melanoma, or a hematological malignancy, comprising administering to a subject in need thereof an effective amount of
(i) an angiogenesis inhibitor; and
(ii) 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5).

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the angiogenesis inhibitor is nintedanib, bevacizumab, sorafenib, sunitinib, thalidomide, dovitinib, regorafenib, or imatinib.

### Claim 18 (depends on 1)

The method of claim 1, wherein the angiogenesis inhibitor is nintedanib.

### Claim 19 (depends on 1)

The method of claim 1, wherein the angiogenesis inhibitor is bevacizumab.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer, ovarian cancer, glioblastoma, kidney cancer, liver cancer, or lung cancer.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cancer is colon cancer.

### Claim 22 (depends on 1)

The method of claim 1, wherein the cancer is refractory, non-responsive, or resistant to chemotherapy and/or haploidentical stem cell transplantation.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cancer is non-responsive or resistant to the angiogenesis inhibitor.

### Claim 24 (depends on 1)

The method of claim 1, wherein the angiogenesis inhibitor and 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5) are administered simultaneously or sequentially.

### Claim 25

A method of treating chemoresistant cancer that is breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, ovarian cancers, neuroblastoma, glioblastoma, kidney cancer, bladder cancer, gastrointestinal stromal tumors, liver cancer, head and neck cancer, lung cancer, melanoma, or a hematological malignancy, comprising administering to a subject in need thereof an effective amount of
(i) an angiogenesis inhibitor; and
(ii) 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5).

### Claim 26 (depends on 25)

The method of claim 25, wherein the cancer is breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, ovarian cancers, neuroblastoma, melanoma, or a hematological malignancy.

### Claim 27 (depends on 25)

The method of claim 25, wherein the cancer is resistant to the angiogenesis inhibitor.

### Claim 28 (depends on 25)

The method of claim 25, wherein the angiogenesis inhibitor is nintedanib.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)
